Evidence map›Paper›PMID 38894897›Full record

ArticleACS medicinal chemistry letters2024

A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR

Oleksandr Grytsai, Maeva Dufies, Julie Le Du, Olivia Rastoin, Leticia Christina Pires Gonçalves, Lou Mateo, Sandra Lacas-Gervais, Yihai Cao, Luc Demange, Gilles Pagès and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Oleksandr GrytsaiUniversité Côte d'Azur, CNRS UMR 7272, Institut de Chimie de Nice, 06108 Nice, France.
Maeva DufiesRoca Therapeutics, 27 Rue du Professeur Delvalle, 06000 Nice, France.
Julie Le DuUniversité Côte d'Azur, CNRS UMR 7272, Institut de Chimie de Nice, 06108 Nice, France.
Olivia RastoinRoca Therapeutics, 27 Rue du Professeur Delvalle, 06000 Nice, France.
Leticia Christina Pires GonçalvesUniversité Côte d'Azur, CNRS UMR 7272, Institut de Chimie de Nice, 06108 Nice, France.
Lou MateoUniversité Côte d'Azur, CNRS UMR 7272, Institut de Chimie de Nice, 06108 Nice, France.
Sandra Lacas-GervaisUniversité Côte d'Azur, CCMA, UAR Sciences, 06103 Nice, France.
Yihai CaoDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Luc DemangeUniversité Côte d'Azur, CNRS UMR 7272, Institut de Chimie de Nice, 06108 Nice, France.
Gilles PagèsRoca Therapeutics, 27 Rue du Professeur Delvalle, 06000 Nice, France.
Rachid BenhidaUniversité Côte d'Azur, CNRS UMR 7272, Institut de Chimie de Nice, 06108 Nice, France.
Cyril RoncoUniversité Côte d'Azur, CNRS UMR 7272, Institut de Chimie de Nice, 06108 Nice, France.ORCID https://orcid.org/0000-0002-9023-5940

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CXCR1/2 biomolecules play vital roles in cancer cell proliferation, tumor inflammation, and angiogenesis, making them attractive drug targets. In clear cell renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC), where CXCR1/2 is overexpressed, inhibition studies are limited. Building upon previous research efforts, we investigated new

Identifiers

PMID38894897
PMCPMC11181512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.